Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee

Bone Marrow Transplantation volume 56, pages 786–797 (2021)Cite this article

Subjects

A Correction to this article was published on 03 May 2021

This article has been updated

Abstract

Systematic reviews apply rigorous methodologies to address a pre-specified, clearly formulated clinical research question. The conclusion that results is often cited to more robustly inform decision-making by clinicians, third-party payers and managed care organizations about the clinical question of interest. While systematic reviews provide a rigorous standard, they may be unfeasible when the task is to create general disease-focused guidelines comprised of multiple clinical practice questions versus a single major clinical practice question. Collaborating transplantation and cellular therapy societal committees also recognize that the quantity and or quality of reference sources may be insufficient for a meaningful systematic review. As the conduct of systematic reviews has evolved over time in terms of grading systems, reporting requirements and use of technology, here we provide current guidance in methodologies, resources for reviewers, and approaches to overcome challenges in conducting systematic reviews in transplantation and cellular therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

References

  1. Jones R, Horowitz M, Wall D, Wingard J, Wolff S, McCarthy P, et al. Evidence-based reviews and the role of blood and marrow transplantation in the treatment of selected disease: an ASBMT policy statement. American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2000;6:523.

  2. Jones R, Horowitz M, Wall D, Wingard J, Wolff S, McCarthy P, et al. ASBMT policy statement regarding the methodology of evidence-based reviews in evaluating the role of blood and marrow transplantation in the treatment of selected diseases. American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2000;6:524–5.

    Article  CAS  Google Scholar 

  3. Schmidt LM, Gotzsche PC. Of mites and men: reference bias in narrative review articles: a systematic review. J Fam Pr. 2005;54:334–8.

    Google Scholar 

  4. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126:376–80.

    Article  CAS  PubMed  Google Scholar 

  5. Petticrew M. Systematic reviews from astronomy to zoology: myths and misconceptions. BMJ. 2001;322:98–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Garritty C, Stevens A, Hamel C, Golfam M, Hutton B, Wolfe D. Knowledge synthesis in evidence-based medicine. Semin Nucl Med. 2019;49:136–44.

    Article  CAS  PubMed  Google Scholar 

  7. Sargeant JM, O’Connor AM. Introduction to systematic reviews in animal agriculture and veterinary medicine. Zoonoses Public Health. 2014;61(Suppl 1):3–9.

    Article  PubMed  Google Scholar 

  8. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26:91–108.

    Article  PubMed  Google Scholar 

  9. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. New York, NY: Academic press; 1985.

  10. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. UK: Oxford Centre for Evidence-Based Medicine Oxford; 2011.

  11. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of the jury. J Clin Oncol. 1999;17:423–9.

    Article  CAS  PubMed  Google Scholar 

  12. Chalmers TC, Berrier J, Sacks HS, Levin H, Reitman D, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. II: replicate variability and comparison of studies that agree and disagree. Stat Med. 1987;6:733–44.

    Article  CAS  PubMed  Google Scholar 

  13. Jones R, Nieto Y, Rizzo JD, Wall D, Wingard JR, McCarthy P Jr, et al. The evolution of the evidence-based review: evaluating the science enhances the art of medicine–statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2005;11:819–22.

    Article  Google Scholar 

  14. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hahn T, Wolff SN, Czuczman M, Fisher RI, Lazarus HM, McCarthy PL, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence-based review. Biol Blood Marrow Transpl. 2001;7:308–31.

    Article  CAS  Google Scholar 

  16. Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, Brozeit G, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transpl. 2003;9:4–37.

    Article  Google Scholar 

  17. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transpl. 2005;11:823–61.

    Article  Google Scholar 

  18. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transpl. 2006;12:1–30.

    Article  CAS  Google Scholar 

  19. Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transpl. 2007;13:1–25.

    Article  Google Scholar 

  20. Oliansky DM, Appelbaum F, Cassileth PA, keating A, Kerr J, Nieto Y, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transpl. 2008;14:137–80.

    Article  Google Scholar 

  21. Oliansky DM, Antin JH, Bennett JM, Deeg HF, Engelhardt C, Heptinstall KV, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transpl. 2009;15:137–72.

    Article  Google Scholar 

  22. Jones RB, Nieto Y, Wall D, Wingard JR, Rizzo JD, Mccarthy PL Jr, et al. Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy statement by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2009;15:761–2.

    Article  Google Scholar 

  23. Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8:iii–iv.1–72

    Article  CAS  PubMed  Google Scholar 

  24. Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2009:CD001055.

  25. University of York NHS Centre for Reviews Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. York, UK: Centre for Reviews and Dissemination, University of York; 2009.

  26. Graham ID, Tetroe J, Gagnon M. Lost in translation: just lost or beginning to find our way? Ann Emerg Med. 2009;54:313–4. discussion 4

    Article  PubMed  Google Scholar 

  27. IOM (Institute of Medicine). In: Eden J, Levit L, Berg A, Morton S, editors. Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The Nationaal Academies Press; 2011.

  28. Thomas J, Kneale D, McKenzie JE, Brennan SE, Bhaumik S. Chapter 2: determining the scope of the review and the questions it will address. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, LiT, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 6.1 (updated September 2020). Cochrane; 2020. Available from http://www.training.cochrane.org/handbook.

  29. Oliansky DM, Larson RA, Weisdorf D, Dillon H, Ratko TA, Wall D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. Biol Blood Marrow Transpl. 2012;18:18–36. Available from http://www.training.cochrane.org/handbook.

    Article  Google Scholar 

  30. Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transpl. 2012;18:505–22.

    Article  CAS  Google Scholar 

  31. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, et al. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:1155–66.

    Article  Google Scholar 

  32. Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transpl. 2011;17:20–47.

    Article  Google Scholar 

  33. DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2019;25:2113–3123.

    Article  Google Scholar 

  34. Dholaria B, Savani BN, Hamilton BK, Oran B, Lui HD, Tallman MS et al. Hematopoietic cell transplantation in the treatment of newly disgnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2020; e-pub ahead of print 20 Sep 2020; https://doi.org/10.1016/j.bbmt.2020.09.020.

  35. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncery TR, Langston A, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001.

    Article  PubMed  Google Scholar 

  36. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246–54.

    Article  PubMed  Google Scholar 

  37. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Morton S, Berg A, Levit L, Eden J. Standards for Initiating a Systematic Review. Finding what works in health care: standards for systematic reviews. Washington, DC: National Academies Press; 2011.

  39. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. Chapter 3: Defining the criteria for including studies and how that will be grouped for synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. 6.1 (updated September 2020). Cochrane; 2020. http://www.training.cochrane.org/handbook.

  40. Moher D, Shamseer, Clarke M, Dhersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRIMSA-P) 2015 statement. Syst Rev. 2015;4:1.

    Article  PubMed  PubMed Central  Google Scholar 

  41. PROSPERO: International prospective register of systematic reviews. (Accessed 13 Aug, 2020 https://www.crd.york.ac.uk/prospero/.)

  42. Cochrane Library. (Accessed 13 Aug, 2020 https://www.cochranelibrary.com/.

  43. F1000 Research. (Accessed 13 Aug, 2020 https://f1000research.com/

  44. Joanna Briggs Institute. (Accessed 13 Aug, 2020 https://joannabriggs.org/.

  45. OSF registries. https://osf.io/registries.

  46. Zenodo (Accessed 13 Aug, 2020 https://zenodo.org/.

  47. Male-specific late effects after hematopoietic cell transplantation. 2020. (Accessed 13 Aug 2020 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020147640.

  48. Wu YP, Aylward BS, Roberts MC, Evans SC. Searching the scientific literature: implications for quantitative and qualitative reviews. Clin Psychol Rev. 2012;32:553–7.

    Article  PubMed  Google Scholar 

  49. Morton S, Berg A, Levit L, Eden J. Standards for Finding and Assessing Individual Studies. Finding what works in health care: standards for systematic reviews. Washington, DC: National Academies Press; 2011.

  50. Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009;62:944–52.

    Article  PubMed  Google Scholar 

  51. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Joannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Altman DG. Measuring agreement. In: Altman DG, editors. Practical Statistics for Medical Research. London, UK: CRC press; 1991.

  54. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383–94.

    Article  PubMed  Google Scholar 

  55. Guyatt GH, Oxman AD, Schűnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–2.

    Article  PubMed  Google Scholar 

  56. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Alonso-Coello P, Schűnemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.

    Article  PubMed  Google Scholar 

  58. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schűnemann HJ, GRADE Working Group. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336:995–8.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60–63.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NH, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ 2019;366:I44898.

    Google Scholar 

  61. Rashidi A, Meybodi MA, Cao W, Chu H, Warkick ED, Devine S, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation in myelodysplastic syndromes: systematic review and meta-analysis. Biol Blood Marrow Transpl. 2020;26:e138–e41.

    Article  CAS  Google Scholar 

  62. Sterne JA, Hernan MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute; 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  64. Aulakh S, Reljic T, Yassine F, Ayala E, Chavez JC, Chanan-Khan A et al. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2020; epub ahead of print 15 May 2020; https://doi.org/10.1016/j.hemonc.2020.05.002.

  65. Parrondo RD, Reljic T, Iqbal M, Ayala E, Tun HW, Kharfan-Dabaja MA et al. Efficacy of autologous and allogeneic hematopoietic cell transplantation in Waldenstrӧm Macroglobulinemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2020; epub ahead of print 2 Jun 2020; https://doi.org/10.1016/j.clml.2020.05.021.

  66. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. A Prod ESRC Methods Program Version 1. 2006;1(April):b92.

    Google Scholar 

  67. Bushman BJ, Wang MC. Vote-counting procedures in meta-analysis. In: Cooper HHL, Valentine JC, editors. The Handbook of Research Synthesis and Meta-Analysis, 2nd edn. New York, NY, US: Russell Sage Foundation; 2009. p. 207–20.

  68. Cwikel J, Behar L, Rabson-Hare J. A comparison of a vote count and a meta-analysis review of intervention research with adult cancer patients. Res Soc Work Pract. 2000;10:139–58.

    Article  Google Scholar 

  69. Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks, CA: SAGE publications, Inc; 2001.

  70. Verbeek J, Ruotsalainen J, Hoving JL. Synthesizing study results in a systematic review. Scand J Work Environ Health. 2012;38:282–90.

    Article  PubMed  Google Scholar 

  71. Anzures-Cabrera J, Higgins JP. Graphical displays for meta-analysis: an overview with suggestions for practice. Res Synth Methods. 2010;1:66–80.

    Article  PubMed  Google Scholar 

  72. Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002;21:1503–11.

    Article  CAS  PubMed  Google Scholar 

  73. Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. Clin Infect Dis. 2020;71:226–36.

    Article  CAS  PubMed  Google Scholar 

  74. Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2015;68:1312–24.

    Article  PubMed  Google Scholar 

  75. Development and Update of the NCCN Guidelines. (Accessed 13 Aug, 2020 https://www.nccn.org/professionals/development.aspx.

  76. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep. 1999;48:1–59.61–6.

    Google Scholar 

  77. Page M, McKenzie J, Bossuty P, Boutron I, Hoffmann T, Mulrow C et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. (Accessed 18 Oct, 2020) https://osf.io/preprints/metaarxiv/v7gm2.

  78. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012;12:181.

    Article  PubMed  PubMed Central  Google Scholar 

  79. APA Publications Communications Board Working Group on Journal Article Reporting Standards. Reporting standards for research in psychology: why do we need them? What might they be? Am Psychol. 2008;63:839–51.

    Article  Google Scholar 

  80. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.

    Article  CAS  PubMed  Google Scholar 

  81. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003;362:1225–30.

    Article  PubMed  Google Scholar 

  82. Khera N. From evidence to clinical practice in blood and marrow transplantation. Blood Rev. 2015;29:351–7.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:143.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–73.

    Article  PubMed  Google Scholar 

  85. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transpl. 2019;25:2305–21.

    Article  CAS  Google Scholar 

  86. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, et al. Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transpl. 2019;54:1868–80.

    Article  CAS  Google Scholar 

  87. Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transpl. 2014;20:600–16.

    Article  CAS  Google Scholar 

  88. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38:655–62.

    PubMed  PubMed Central  Google Scholar 

  89. Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, López-Guillelrmo A, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98:1014–21.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Krӧger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29:2126–33.

    Article  Google Scholar 

  91. Kharfan-Dabaja MA, Kumar A, Hamadani M, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2016;22:2117–25.

    Article  Google Scholar 

  92. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: aninternational collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2017;23:1826–38.

    Article  Google Scholar 

  93. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715–22.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazii F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157–e167.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Keith A. Laycock, PhD, ELS, for scientific editing and Matthew J. Page, PhD for critical review of the paper.

Funding

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health supported this publication under Award Number K23HL150232 (SMB). AS is the recipient of an American Society of Scholar Award. The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the NHLBI and the National Institute of Allergy and Infectious Diseases (NIAID); R21HL140314 and U01HL128568 from the NHLBI; HHSH250201700006C, SC1MC31881-01-00 and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014-18-1-2850, N00014-18-1-2888, and N00014-20-1-2705 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01CA218285, R01CA231141, R01AI128775, R01HL129472, R01HL130388, R01HL131731, U01AI069197, U01AI126612 and BARDA. The views expressed in this article do not reflect the official policy or position of the NIH, the Department of the Navy, the Department of Defense, HRSA or any other agency of the United States Government.

Author information

Author notes

  1. These authors contributed equally: Akshay Sharma, Sherif M. Badawy

Authors and Affiliations

  1. Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN, USA

    Akshay Sharma

  2. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Sherif M. Badawy

  3. Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA

    Sherif M. Badawy

  4. Medical College of Wisconsin, Milwaukee, WI, USA

    Elizabeth M. Suelzer

  5. Division of Hematology/Oncology, Mayo Clinic Florida, Jacksonville, FL, USA

    Hemant S. Murthy

  6. Division of Pediatric Hematology/Oncology, Louisiana State University Health Sciences Center / Children’s Hospital of New Orleans, New Orleans, LA, USA

    Pinki Prasad

  7. Department of Pediatrics, University of Colorado School of Medicine, Blood and Marrow Transplant and Cellular Therapy Program, Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO, USA

    Hesham Eissa

  8. Fred Hutchinson Cancer Research Center and Department of Pediatrics, University of Washington, Seattle, WA, USA

    Paul A. Carpenter

  9. Department of Medicine, BMT and Cellular Therapy Program, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

    Mehdi Hamadani

  10. EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France

    Myriam Labopin

  11. Department of Hematology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

    Hélène Schoemans

  12. Division of Hematology, University Hospital Basel, Basel, Switzerland

    André Tichelli

  13. Department of Pediatrics, Division of Hematology and Oncology, and BMT, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

    Rachel Phelan

  14. Department of Hematology and Medical Oncology, Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

    Betty K. Hamilton

  15. Division of Pediatric Hematology, Children’s Hospital of Orange County, Orange, CA, USA

    David Buchbinder

  16. University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, USA

    Annie Im

  17. Division of Hematology, University of Colorado Anschutz Medical Center, Aurora, CO, USA

    Rebecca Hunter

  18. Division of Biostatistics, Medical College of Wisconsin and Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

    Ruta Brazauskas

  19. Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

    Linda J. Burns

Authors
  1. Akshay Sharma
    View author publications

    Search author on:PubMed Google Scholar

  2. Sherif M. Badawy
    View author publications

    Search author on:PubMed Google Scholar

  3. Elizabeth M. Suelzer
    View author publications

    Search author on:PubMed Google Scholar

  4. Hemant S. Murthy
    View author publications

    Search author on:PubMed Google Scholar

  5. Pinki Prasad
    View author publications

    Search author on:PubMed Google Scholar

  6. Hesham Eissa
    View author publications

    Search author on:PubMed Google Scholar

  7. Paul A. Carpenter
    View author publications

    Search author on:PubMed Google Scholar

  8. Mehdi Hamadani
    View author publications

    Search author on:PubMed Google Scholar

  9. Myriam Labopin
    View author publications

    Search author on:PubMed Google Scholar

  10. Hélène Schoemans
    View author publications

    Search author on:PubMed Google Scholar

  11. André Tichelli
    View author publications

    Search author on:PubMed Google Scholar

  12. Rachel Phelan
    View author publications

    Search author on:PubMed Google Scholar

  13. Betty K. Hamilton
    View author publications

    Search author on:PubMed Google Scholar

  14. David Buchbinder
    View author publications

    Search author on:PubMed Google Scholar

  15. Annie Im
    View author publications

    Search author on:PubMed Google Scholar

  16. Rebecca Hunter
    View author publications

    Search author on:PubMed Google Scholar

  17. Ruta Brazauskas
    View author publications

    Search author on:PubMed Google Scholar

  18. Linda J. Burns
    View author publications

    Search author on:PubMed Google Scholar

Contributions

AS wrote the first draft of the paper. SB and LJB critically reviewed and wrote several sections. AS and SB contributed equally to the paper. All authors provided input, reviewed the final paper, and agreed with its content.

Corresponding author

Correspondence to Linda J. Burns.

Ethics declarations

Conflict of interest

AS is a paid consultant for Spotlight Therapeutics and CRISPR Therapeutics/Vertex Pharmaceuticals and Novartis. Between 2017 and 2020, Hélène Schoemans has participated in advisory boards for Incyte (2018) and Janssen & Novartis (2020). She has received speaker’s fees from Jazz Pharmaceuticals (2017); Novartis & Incyte (2018) and Incyte, Jazz Pharmaceuticals & Takeda (2019). She has received travel grants from EBMT (2017); EBMT, Celgene & Abbvie (2018); EBMT & Incyte (2019) and EBMT & Gilead (2020). Research funding was also received from Novartis for an investigator-initiated study and consultancy (2020). None of the other authors has a financial disclosure to make.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is co-published in the journals Bone Marrow Transplantation and Transplantation and Cellular Therapy https://doi.org/10.1038/s41409-020-01199-1 or https://doi.org/10.1016/j.jtct.2020.12.002

The original online version of this article was revised: the Funding information was incorrect.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Badawy, S.M., Suelzer, E.M. et al. Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. Bone Marrow Transplant 56, 786–797 (2021). https://doi.org/10.1038/s41409-020-01199-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-020-01199-1

This article is cited by

Search

Advanced search

Quick links